Media headlines about Cascadian Therapeutics (NASDAQ:CASC) have trended somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cascadian Therapeutics earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.6042455484566 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
CASC stock opened at $9.98 on Wednesday. The stock has a market capitalization of $506.61, a price-to-earnings ratio of -7.48 and a beta of 3.79. Cascadian Therapeutics has a 1-year low of $3.18 and a 1-year high of $10.21.
Several brokerages recently issued reports on CASC. BidaskClub lowered Cascadian Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, March 7th. Cantor Fitzgerald set a $10.00 price target on Cascadian Therapeutics and gave the stock a “hold” rating in a research report on Friday, March 9th. ValuEngine upgraded Cascadian Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 31st. Raymond James Financial lowered Cascadian Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 31st. Finally, Zacks Investment Research lowered Cascadian Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $6.17.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Cascadian Therapeutics (CASC) Stock Price” was originally published by BBNS and is the sole property of of BBNS. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://baseballnewssource.com/2018/03/21/cascadian-therapeutics-casc-receives-daily-media-sentiment-score-of-0-07/2027522.html.
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.